NO311716B1 - Nye pyrrolforbindelser, samt fremstilling og anvendelse derav - Google Patents
Nye pyrrolforbindelser, samt fremstilling og anvendelse derav Download PDFInfo
- Publication number
- NO311716B1 NO311716B1 NO19985495A NO985495A NO311716B1 NO 311716 B1 NO311716 B1 NO 311716B1 NO 19985495 A NO19985495 A NO 19985495A NO 985495 A NO985495 A NO 985495A NO 311716 B1 NO311716 B1 NO 311716B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- branched
- linear
- optionally substituted
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 59
- 150000003233 pyrroles Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 125000004429 atom Chemical group 0.000 claims abstract description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 11
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims description 6
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- VBIMVLOIUBLUKZ-UHFFFAOYSA-N 1,3-bis(4-fluorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrrole Chemical compound C1=CC(F)=CC=C1C1=C2CCCC2=C(C=2C=CC(F)=CC=2)N1 VBIMVLOIUBLUKZ-UHFFFAOYSA-N 0.000 claims description 3
- PWORIKUKVBOCDD-UHFFFAOYSA-N 1,3-bis(4-fluorophenyl)-4,5,6,7-tetrahydro-2h-isoindole Chemical group C1=CC(F)=CC=C1C1=C2CCCCC2=C(C=2C=CC(F)=CC=2)N1 PWORIKUKVBOCDD-UHFFFAOYSA-N 0.000 claims description 3
- -1 acetic acid Chemical class 0.000 claims description 3
- GYWDQAIIDHAFSZ-UHFFFAOYSA-N chembl341878 Chemical compound C1CC(C=23)CC1C3=C(C=1C=CC=CC=1)NC=2C1=CC=CC=C1 GYWDQAIIDHAFSZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- PEIGDJODVZVECV-UHFFFAOYSA-N 5,6-dimethyl-1,3-diphenyl-4,5,6,7-tetrahydro-2h-isoindole Chemical compound C1C(C)C(C)CC=2C1=C(C=1C=CC=CC=1)NC=2C1=CC=CC=C1 PEIGDJODVZVECV-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 2
- BVZXSBMLTOYNIL-UHFFFAOYSA-N chembl143776 Chemical compound C1=CC(F)=CC=C1C1=C2C(C3)CCC3C2=C(C=2C=CC(F)=CC=2)N1 BVZXSBMLTOYNIL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 150000002681 magnesium compounds Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000006823 (C1-C6) acyl group Chemical group 0.000 abstract 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 1
- YPWFNLSXQIGJCK-UHFFFAOYSA-N 7-oxabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1O2 YPWFNLSXQIGJCK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002585 base Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000000047 product Substances 0.000 description 75
- 238000002844 melting Methods 0.000 description 32
- 230000008018 melting Effects 0.000 description 32
- 238000004452 microanalysis Methods 0.000 description 29
- 239000000758 substrate Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 22
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 150000001993 dienes Chemical class 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 101150071146 COX2 gene Proteins 0.000 description 6
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 101150000187 PTGS2 gene Proteins 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- VJAXJFWMMZTLLB-UHFFFAOYSA-N (6-benzoylcyclohex-3-en-1-yl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1CC=CCC1C(=O)C1=CC=CC=C1 VJAXJFWMMZTLLB-UHFFFAOYSA-N 0.000 description 3
- MXZHREAIKLZWIM-UHFFFAOYSA-N 1,3-diphenyl-4,5,6,7-tetrahydroisoindol-2-amine Chemical compound NN1C(C=2C=CC=CC=2)=C2CCCCC2=C1C1=CC=CC=C1 MXZHREAIKLZWIM-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AQRCGRWLZDMDSZ-UHFFFAOYSA-N (6-benzoyl-3,4-dimethylcyclohex-3-en-1-yl)-phenylmethanone Chemical compound C1C(C)=C(C)CC(C(=O)C=2C=CC=CC=2)C1C(=O)C1=CC=CC=C1 AQRCGRWLZDMDSZ-UHFFFAOYSA-N 0.000 description 2
- NRAWDOUOQWSMJF-UHFFFAOYSA-N 1,3-bis(4-chlorophenyl)-4,5,6,7-tetrahydro-2h-isoindole Chemical compound C1=CC(Cl)=CC=C1C1=C2CCCCC2=C(C=2C=CC(Cl)=CC=2)N1 NRAWDOUOQWSMJF-UHFFFAOYSA-N 0.000 description 2
- QYSGPZTTXAXARH-UHFFFAOYSA-N 1,3-diphenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrrole Chemical compound C1CCC=2C1=C(C=1C=CC=CC=1)NC=2C1=CC=CC=C1 QYSGPZTTXAXARH-UHFFFAOYSA-N 0.000 description 2
- OXUZAAMYHTYRBZ-UHFFFAOYSA-N 1,4-bis(4-fluorophenyl)but-2-ene-1,4-dione Chemical compound C1=CC(F)=CC=C1C(=O)C=CC(=O)C1=CC=C(F)C=C1 OXUZAAMYHTYRBZ-UHFFFAOYSA-N 0.000 description 2
- SDJHPPZKZZWAKF-UHFFFAOYSA-N 2,3-dimethylbuta-1,3-diene Chemical compound CC(=C)C(C)=C SDJHPPZKZZWAKF-UHFFFAOYSA-N 0.000 description 2
- YGYSGVUREDDVOM-UHFFFAOYSA-N 2-[5-(2-amino-4-fluorophenyl)-4-azatricyclo[5.2.1.02,6]deca-2,5-dien-3-yl]-5-fluoroaniline Chemical compound NC1=CC(F)=CC=C1C1=C2C(C3)CCC3C2=C(C=2C(=CC(F)=CC=2)N)N1 YGYSGVUREDDVOM-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 2
- ZXMUVHAAKLFYSY-UHFFFAOYSA-N [6-(4-chlorobenzoyl)cyclohex-3-en-1-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1C(C(=O)C=2C=CC(Cl)=CC=2)CC=CC1 ZXMUVHAAKLFYSY-UHFFFAOYSA-N 0.000 description 2
- CUDSMTPHVAFJFT-UHFFFAOYSA-N [6-(4-methoxybenzoyl)cyclohex-3-en-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1C(C(=O)C=2C=CC(OC)=CC=2)CC=CC1 CUDSMTPHVAFJFT-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UJLLGVRXLJHBKU-UHFFFAOYSA-N (3-benzoyl-2-bicyclo[2.2.2]oct-5-enyl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1C(C=C2)CCC2C1C(=O)C1=CC=CC=C1 UJLLGVRXLJHBKU-UHFFFAOYSA-N 0.000 description 1
- NMSRALOLNIBERV-SYDPRGILSA-N (3as,6ar)-4,5,6,6a-tetrahydro-3ah-cyclopenta[c]furan-1,3-dione Chemical compound C1CC[C@@H]2C(=O)OC(=O)[C@@H]21 NMSRALOLNIBERV-SYDPRGILSA-N 0.000 description 1
- RFMWHPPDFADBJK-UHFFFAOYSA-N (4-benzoyl-1-benzylpyrrolidin-3-yl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C(C(C1)C(=O)C=2C=CC=CC=2)CN1CC1=CC=CC=C1 RFMWHPPDFADBJK-UHFFFAOYSA-N 0.000 description 1
- WYCXGQSQHAXLPK-VAWYXSNFSA-N (e)-1,4-diphenylbut-2-ene-1,4-dione Chemical compound C=1C=CC=CC=1C(=O)\C=C\C(=O)C1=CC=CC=C1 WYCXGQSQHAXLPK-VAWYXSNFSA-N 0.000 description 1
- URUZPYOPRCOJJA-AATRIKPKSA-N (e)-1,4-dithiophen-2-ylbut-2-ene-1,4-dione Chemical compound C=1C=CSC=1C(=O)\C=C\C(=O)C1=CC=CS1 URUZPYOPRCOJJA-AATRIKPKSA-N 0.000 description 1
- CRQKUEDOLYFKID-UHFFFAOYSA-N 1,3-bis(4-chlorophenyl)-4,7-dihydro-2h-isoindole Chemical compound C1=CC(Cl)=CC=C1C1=C2CC=CCC2=C(C=2C=CC(Cl)=CC=2)N1 CRQKUEDOLYFKID-UHFFFAOYSA-N 0.000 description 1
- ARUYCRKCQSIDIQ-UHFFFAOYSA-N 1,3-bis(4-imidazol-1-ylphenyl)-4,5,6,7-tetrahydro-2h-isoindole;dihydrochloride Chemical compound Cl.Cl.C1CCCC=2C1=C(C=1C=CC(=CC=1)N1C=NC=C1)NC=2C(C=C1)=CC=C1N1C=CN=C1 ARUYCRKCQSIDIQ-UHFFFAOYSA-N 0.000 description 1
- ZPDPPKPKRWYOFW-UHFFFAOYSA-N 1,3-bis(4-imidazol-1-ylphenyl)-4,7-dihydro-2h-isoindole Chemical compound C1C=CCC=2C1=C(C=1C=CC(=CC=1)N1C=NC=C1)NC=2C(C=C1)=CC=C1N1C=CN=C1 ZPDPPKPKRWYOFW-UHFFFAOYSA-N 0.000 description 1
- QBHFMNOQYWUXOU-UHFFFAOYSA-N 1,3-bis(4-methoxyphenyl)-4,5,6,7-tetrahydro-2h-isoindole Chemical compound C1=CC(OC)=CC=C1C1=C2CCCCC2=C(C=2C=CC(OC)=CC=2)N1 QBHFMNOQYWUXOU-UHFFFAOYSA-N 0.000 description 1
- HNRFCLCIOMFCBC-UHFFFAOYSA-N 1,3-bis(4-methoxyphenyl)-4,7-dihydro-2h-isoindole Chemical compound C1=CC(OC)=CC=C1C1=C2CC=CCC2=C(C=2C=CC(OC)=CC=2)N1 HNRFCLCIOMFCBC-UHFFFAOYSA-N 0.000 description 1
- BYUWZYHJHNOICB-UHFFFAOYSA-N 1,3-diphenyl-4,7-dihydro-2h-isoindole Chemical compound C1C=CCC=2C1=C(C=1C=CC=CC=1)NC=2C1=CC=CC=C1 BYUWZYHJHNOICB-UHFFFAOYSA-N 0.000 description 1
- CLSUGVFFCXOBBU-UHFFFAOYSA-N 1,4-bis(2,4-difluorophenyl)but-2-ene-1,4-dione Chemical compound FC1=CC(F)=CC=C1C(=O)C=CC(=O)C1=CC=C(F)C=C1F CLSUGVFFCXOBBU-UHFFFAOYSA-N 0.000 description 1
- HWHXDAMZDNEPPF-UHFFFAOYSA-N 1,4-bis(3,4-difluorophenyl)but-2-ene-1,4-dione Chemical compound C1=C(F)C(F)=CC=C1C(=O)C=CC(=O)C1=CC=C(F)C(F)=C1 HWHXDAMZDNEPPF-UHFFFAOYSA-N 0.000 description 1
- NOWZMUNUVDBDQQ-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)but-2-ene-1,4-dione Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC(=O)C1=CC=C(Cl)C=C1 NOWZMUNUVDBDQQ-UHFFFAOYSA-N 0.000 description 1
- AZKWRDCPOPVYMS-UHFFFAOYSA-N 1,4-bis(4-fluoro-2-nitrophenyl)but-2-ene-1,4-dione Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1C(=O)C=CC(=O)C1=CC=C(F)C=C1[N+]([O-])=O AZKWRDCPOPVYMS-UHFFFAOYSA-N 0.000 description 1
- MENHZMBJJYQMOZ-UHFFFAOYSA-N 1,4-bis(4-fluoro-3-nitrophenyl)but-2-ene-1,4-dione Chemical compound C1=C(F)C([N+](=O)[O-])=CC(C(=O)C=CC(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 MENHZMBJJYQMOZ-UHFFFAOYSA-N 0.000 description 1
- CEXKMZRIOMSVLG-UHFFFAOYSA-N 1,4-bis(4-methoxyphenyl)but-2-ene-1,4-dione Chemical compound C1=CC(OC)=CC=C1C(=O)C=CC(=O)C1=CC=C(OC)C=C1 CEXKMZRIOMSVLG-UHFFFAOYSA-N 0.000 description 1
- ILPFELOVNBBXIR-UHFFFAOYSA-N 1,4-bis(5-fluoropyridin-2-yl)but-2-ene-1,4-dione Chemical compound N1=CC(F)=CC=C1C(=O)C=CC(=O)C1=CC=C(F)C=N1 ILPFELOVNBBXIR-UHFFFAOYSA-N 0.000 description 1
- ZGLFBWHTXOEBIG-UHFFFAOYSA-N 1,4-bis(6-fluoropyridin-3-yl)but-2-ene-1,4-dione Chemical compound C1=NC(F)=CC=C1C(=O)C=CC(=O)C1=CC=C(F)N=C1 ZGLFBWHTXOEBIG-UHFFFAOYSA-N 0.000 description 1
- QCDYXWYDNSFEAJ-UHFFFAOYSA-N 1,4-bis(furan-2-yl)but-2-ene-1,4-dione Chemical compound C=1C=COC=1C(=O)C=CC(=O)C1=CC=CO1 QCDYXWYDNSFEAJ-UHFFFAOYSA-N 0.000 description 1
- MPLAGUFMYYULLM-UHFFFAOYSA-N 1,4-dipyridin-4-ylbut-2-ene-1,4-dione Chemical compound C=1C=NC=CC=1C(=O)C=CC(=O)C1=CC=NC=C1 MPLAGUFMYYULLM-UHFFFAOYSA-N 0.000 description 1
- RULFVHVCCYMYFH-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-(4-imidazol-1-ylphenyl)-4,5,6,7-tetrahydro-2h-isoindole Chemical compound C1=CC(F)=CC=C1C1=C2CCCCC2=C(C=2C=CC(=CC=2)N2C=NC=C2)N1 RULFVHVCCYMYFH-UHFFFAOYSA-N 0.000 description 1
- GQAZUTMQTCRQDM-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)-3-phenyl-4,5,6,7-tetrahydro-2h-isoindole Chemical compound C1=CC(SC)=CC=C1C1=C2CCCCC2=C(C=2C=CC=CC=2)N1 GQAZUTMQTCRQDM-UHFFFAOYSA-N 0.000 description 1
- GDUKFHGAFVRLRQ-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)-3-phenyl-4,7-dihydro-2h-isoindole Chemical compound C1=CC(SC)=CC=C1C1=C2CC=CCC2=C(C=2C=CC=CC=2)N1 GDUKFHGAFVRLRQ-UHFFFAOYSA-N 0.000 description 1
- XREDBMQNKAWFGA-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-isoindole Chemical group C1=CCC2CNCC2=C1 XREDBMQNKAWFGA-UHFFFAOYSA-N 0.000 description 1
- PDASQEFCOAXALW-UHFFFAOYSA-N 2-(1,3-diphenyl-4,5,6,7-tetrahydroisoindol-2-yl)acetic acid Chemical compound OC(=O)CN1C(C=2C=CC=CC=2)=C2CCCCC2=C1C1=CC=CC=C1 PDASQEFCOAXALW-UHFFFAOYSA-N 0.000 description 1
- ZTTOZKCURFATEO-UHFFFAOYSA-N 2-(1,3-diphenyl-4,7-dihydroisoindol-2-yl)acetic acid Chemical compound OC(=O)CN1C(C=2C=CC=CC=2)=C2CC=CCC2=C1C1=CC=CC=C1 ZTTOZKCURFATEO-UHFFFAOYSA-N 0.000 description 1
- WEROLDWTIDUANL-UHFFFAOYSA-N 2-methyl-1,3-diphenyl-4,5,6,7-tetrahydroisoindole Chemical compound CN1C(C=2C=CC=CC=2)=C2CCCCC2=C1C1=CC=CC=C1 WEROLDWTIDUANL-UHFFFAOYSA-N 0.000 description 1
- LCMBJXIWZPLMFH-UHFFFAOYSA-N 2-methyl-1,3-diphenyl-4,7-dihydroisoindole Chemical compound CN1C(C=2C=CC=CC=2)=C2CC=CCC2=C1C1=CC=CC=C1 LCMBJXIWZPLMFH-UHFFFAOYSA-N 0.000 description 1
- 235000020926 24-h fasting Nutrition 0.000 description 1
- PSEHUWJUWCPCFD-UHFFFAOYSA-N 3,5-bis(4-fluoro-2-nitrophenyl)-4-azatricyclo[5.2.1.02,6]deca-2,5-diene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1C1=C2C(C3)CCC3C2=C(C=2C(=CC(F)=CC=2)[N+]([O-])=O)N1 PSEHUWJUWCPCFD-UHFFFAOYSA-N 0.000 description 1
- UGAHBQXITFMZQO-UHFFFAOYSA-N 3,5-diphenyl-4-azatricyclo[5.2.1.02,6]deca-2,5,8-triene Chemical compound C1C2C=CC1C=1C2=C(C=2C=CC=CC=2)NC=1C1=CC=CC=C1 UGAHBQXITFMZQO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KREIXPXIQNUCSB-UHFFFAOYSA-N 5-[5-(3-amino-4-fluorophenyl)-4-azatricyclo[5.2.1.02,6]deca-2,5-dien-3-yl]-2-fluoroaniline Chemical compound C1=C(F)C(N)=CC(C2=C3C4CCC(C4)C3=C(N2)C=2C=C(N)C(F)=CC=2)=C1 KREIXPXIQNUCSB-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WVUUIOAZOVCOPK-UHFFFAOYSA-N N1=CC(F)=CC=C1C1=C2C(C3)CCC3C2=C(C=2N=CC(F)=CC=2)N1 Chemical compound N1=CC(F)=CC=C1C1=C2C(C3)CCC3C2=C(C=2N=CC(F)=CC=2)N1 WVUUIOAZOVCOPK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101710195703 Oxygen-dependent coproporphyrinogen-III oxidase Proteins 0.000 description 1
- 101710200437 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- QEIXIARZKUQOCM-UHFFFAOYSA-N [2-(4-fluorobenzoyl)cyclohexyl]-(4-imidazol-1-ylphenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1C(C(=O)C=2C=CC(=CC=2)N2C=NC=C2)CCCC1 QEIXIARZKUQOCM-UHFFFAOYSA-N 0.000 description 1
- XWPVWZHDPUMNQR-UHFFFAOYSA-N [3-(2,4-difluorobenzoyl)-2-bicyclo[2.2.1]hept-5-enyl]-(2,4-difluorophenyl)methanone Chemical compound FC1=CC(F)=CC=C1C(=O)C1C(C(=O)C=2C(=CC(F)=CC=2)F)C2CC1C=C2 XWPVWZHDPUMNQR-UHFFFAOYSA-N 0.000 description 1
- PGVQMYAGYJGQNT-UHFFFAOYSA-N [3-(4-fluoro-2-nitrobenzoyl)-2-bicyclo[2.2.1]hept-5-enyl]-(4-fluoro-2-nitrophenyl)methanone Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1C(=O)C1C(C(=O)C=2C(=CC(F)=CC=2)[N+]([O-])=O)C2CC1C=C2 PGVQMYAGYJGQNT-UHFFFAOYSA-N 0.000 description 1
- GPZMILBAESEVOO-UHFFFAOYSA-N [3-(4-fluoro-3-nitrobenzoyl)-2-bicyclo[2.2.1]hept-5-enyl]-(4-fluoro-3-nitrophenyl)methanone Chemical compound C1=C(F)C([N+](=O)[O-])=CC(C(=O)C2C(C3CC2C=C3)C(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 GPZMILBAESEVOO-UHFFFAOYSA-N 0.000 description 1
- KDJGJQBJDJSVAP-UHFFFAOYSA-N [3-(4-fluorobenzoyl)-2-bicyclo[2.2.2]oct-5-enyl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1C(C(=O)C=2C=CC(F)=CC=2)C2CCC1C=C2 KDJGJQBJDJSVAP-UHFFFAOYSA-N 0.000 description 1
- VBKOUFSEYZVSIF-UHFFFAOYSA-N [3-(furan-2-carbonyl)-2-bicyclo[2.2.1]hept-5-enyl]-(furan-2-yl)methanone Chemical compound C=1C=COC=1C(=O)C1C(C=C2)CC2C1C(=O)C1=CC=CO1 VBKOUFSEYZVSIF-UHFFFAOYSA-N 0.000 description 1
- SSVQCUSLJVVRCA-UHFFFAOYSA-M [Br-].CSC1=CC=C([Mg+])C=C1 Chemical compound [Br-].CSC1=CC=C([Mg+])C=C1 SSVQCUSLJVVRCA-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- RXUBZLMIGSAPEJ-UHFFFAOYSA-N benzyl n-aminocarbamate Chemical compound NNC(=O)OCC1=CC=CC=C1 RXUBZLMIGSAPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- IMVOJEMXLCTUSD-UHFFFAOYSA-N chembl139721 Chemical compound C1=CC(F)=CC=C1C1=C2C(C=C3)CC3C2=C(C=2C=CC(F)=CC=2)N1 IMVOJEMXLCTUSD-UHFFFAOYSA-N 0.000 description 1
- XSQIFOBXHQHFTI-UHFFFAOYSA-N chembl343701 Chemical compound C1CC(C=23)CCC1C3=C(C=1C=CC=CC=1)NC=2C1=CC=CC=C1 XSQIFOBXHQHFTI-UHFFFAOYSA-N 0.000 description 1
- UZHUVVLOHLBXEC-UHFFFAOYSA-N chembl544620 Chemical compound Cl.Cl.C1CC2CC1C=1C2=C(C=2C=CN=CC=2)NC=1C1=CC=NC=C1 UZHUVVLOHLBXEC-UHFFFAOYSA-N 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
- BVUQKCCKUOSAEV-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=[C-]C=C1 BVUQKCCKUOSAEV-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QVQJFPOHZLTCPI-UHFFFAOYSA-N n-(1,3-diphenyl-4,5,6,7-tetrahydroisoindol-2-yl)-n-methylsulfonylmethanesulfonamide Chemical compound CS(=O)(=O)N(S(C)(=O)=O)N1C(C=2C=CC=CC=2)=C2CCCCC2=C1C1=CC=CC=C1 QVQJFPOHZLTCPI-UHFFFAOYSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- QXYYCFRAKIKYCA-UHFFFAOYSA-N tert-butyl 2-(1,3-diphenyl-4,7-dihydroisoindol-2-yl)acetate Chemical compound CC(C)(C)OC(=O)CN1C(C=2C=CC=CC=2)=C2CC=CCC2=C1C1=CC=CC=C1 QXYYCFRAKIKYCA-UHFFFAOYSA-N 0.000 description 1
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/72—4,7-Endo-alkylene-iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9714840A FR2771412B1 (fr) | 1997-11-26 | 1997-11-26 | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985495D0 NO985495D0 (no) | 1998-11-25 |
| NO985495L NO985495L (no) | 1999-05-27 |
| NO311716B1 true NO311716B1 (no) | 2002-01-14 |
Family
ID=9513802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985495A NO311716B1 (no) | 1997-11-26 | 1998-11-25 | Nye pyrrolforbindelser, samt fremstilling og anvendelse derav |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6063804A (ja) |
| EP (1) | EP0921119B1 (ja) |
| JP (1) | JPH11228538A (ja) |
| CN (1) | CN1126737C (ja) |
| AT (1) | ATE244221T1 (ja) |
| AU (1) | AU739179B2 (ja) |
| BR (1) | BR9805053A (ja) |
| CA (1) | CA2254521C (ja) |
| DE (1) | DE69816004T2 (ja) |
| DK (1) | DK0921119T3 (ja) |
| ES (1) | ES2202775T3 (ja) |
| FR (1) | FR2771412B1 (ja) |
| HK (1) | HK1020945A1 (ja) |
| HU (1) | HUP9802749A2 (ja) |
| NO (1) | NO311716B1 (ja) |
| NZ (1) | NZ333000A (ja) |
| PL (1) | PL329894A1 (ja) |
| PT (1) | PT921119E (ja) |
| ZA (1) | ZA9810834B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| ES2236007T3 (es) * | 1999-12-08 | 2005-07-16 | Pharmacia Corporation | Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido. |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| US7695736B2 (en) | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
| UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| KR100821915B1 (ko) | 2006-11-10 | 2008-04-16 | 한양대학교 산학협력단 | 2번 위치에 엑소 메틸렌기를 가지는 고리화합물이 치환된 다중 고리화합물 및 이의 제조방법 |
| EP2838881B1 (en) * | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417202B1 (en) * | 1996-07-11 | 2002-07-09 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin-and TNF antagonists |
-
1997
- 1997-11-26 FR FR9714840A patent/FR2771412B1/fr not_active Expired - Fee Related
-
1998
- 1998-11-24 CA CA002254521A patent/CA2254521C/fr not_active Expired - Fee Related
- 1998-11-25 BR BR9805053-2A patent/BR9805053A/pt not_active IP Right Cessation
- 1998-11-25 PT PT98402926T patent/PT921119E/pt unknown
- 1998-11-25 EP EP98402926A patent/EP0921119B1/fr not_active Expired - Lifetime
- 1998-11-25 ES ES98402926T patent/ES2202775T3/es not_active Expired - Lifetime
- 1998-11-25 PL PL98329894A patent/PL329894A1/xx unknown
- 1998-11-25 AT AT98402926T patent/ATE244221T1/de not_active IP Right Cessation
- 1998-11-25 DE DE69816004T patent/DE69816004T2/de not_active Expired - Fee Related
- 1998-11-25 NZ NZ333000A patent/NZ333000A/xx unknown
- 1998-11-25 JP JP10333554A patent/JPH11228538A/ja active Pending
- 1998-11-25 NO NO19985495A patent/NO311716B1/no unknown
- 1998-11-25 DK DK98402926T patent/DK0921119T3/da active
- 1998-11-25 US US09/199,640 patent/US6063804A/en not_active Expired - Fee Related
- 1998-11-26 ZA ZA9810834A patent/ZA9810834B/xx unknown
- 1998-11-26 AU AU94165/98A patent/AU739179B2/en not_active Ceased
- 1998-11-26 CN CN98122801A patent/CN1126737C/zh not_active Expired - Fee Related
- 1998-11-26 HU HU9802749A patent/HUP9802749A2/hu unknown
-
1999
- 1999-09-03 US US09/390,416 patent/US6114360A/en not_active Expired - Fee Related
- 1999-12-03 HK HK99105666A patent/HK1020945A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0921119A1 (fr) | 1999-06-09 |
| CN1126737C (zh) | 2003-11-05 |
| ATE244221T1 (de) | 2003-07-15 |
| FR2771412B1 (fr) | 2000-04-28 |
| HUP9802749A2 (hu) | 2001-02-28 |
| DE69816004T2 (de) | 2004-04-29 |
| ZA9810834B (en) | 1999-05-31 |
| NO985495L (no) | 1999-05-27 |
| CA2254521A1 (fr) | 1999-05-26 |
| CN1222509A (zh) | 1999-07-14 |
| FR2771412A1 (fr) | 1999-05-28 |
| EP0921119B1 (fr) | 2003-07-02 |
| HU9802749D0 (en) | 1999-01-28 |
| PL329894A1 (en) | 1999-06-07 |
| PT921119E (pt) | 2003-10-31 |
| ES2202775T3 (es) | 2004-04-01 |
| CA2254521C (fr) | 2003-10-28 |
| US6063804A (en) | 2000-05-16 |
| AU739179B2 (en) | 2001-10-04 |
| DK0921119T3 (da) | 2003-10-20 |
| NO985495D0 (no) | 1998-11-25 |
| NZ333000A (en) | 2000-04-28 |
| HK1020945A1 (en) | 2000-05-26 |
| DE69816004D1 (de) | 2003-08-07 |
| US6114360A (en) | 2000-09-05 |
| BR9805053A (pt) | 2000-02-01 |
| AU9416598A (en) | 1999-06-17 |
| JPH11228538A (ja) | 1999-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5542196B2 (ja) | １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用 | |
| JP4602076B2 (ja) | 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物 | |
| AU2017279878B2 (en) | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | |
| NO311716B1 (no) | Nye pyrrolforbindelser, samt fremstilling og anvendelse derav | |
| US20130090331A1 (en) | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase | |
| WO2006077366A1 (en) | Indoles useful in the treatment of inflammation | |
| MX2007009429A (es) | Pirrolopirimidinas utiles como inhibidores de proteinas cinasas. | |
| CA2661605A1 (en) | Hydantoin derivatives useful as antibacterial agents | |
| WO2018049296A1 (en) | Heteroaryl inhibitors of pad4 | |
| CA2570363A1 (en) | Indoles useful in the treatment of inflammation | |
| IL190280A (en) | Steamed heterocyclic compounds, their pharmaceutical compositions and their use in the treatment of conditions | |
| NO851862L (no) | Fremgangsmaate ved fremstilling av nye pyrrolobenzimidazoler | |
| HUE031585T2 (en) | Sulfonamide Compounds with TRPM8 Antagonist Activity | |
| Patel et al. | Metal-free synthesis of aminomethylated imidazoheterocycles: dual role of tert-butyl hydroperoxide as both an oxidant and a methylene source | |
| US20210059992A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| CA2909464A1 (en) | Substituted condensed pyrimidine compounds | |
| CA3225439A1 (en) | Cdk2 inhibitors and methods of using the same | |
| Lopchuk et al. | Synthesis of 2-and 3-Indolylpyrroles via 1, 3-Dipolar Cycloadditions of Münchnones and Nitroalkenes | |
| US20160152624A1 (en) | Novel substituted condensed pyrimidine compounds | |
| Zhang et al. | Water-assisted metal-free catalyzed cyclization of 2-alkynylarylketones: a facile approach to indenones | |
| NO151893B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 3h-nafto(1,2-d)imidazolderivater | |
| Yasui et al. | A novel method for the synthesis of 3, 4-disubstitutedpyrrole-2, 5-dicarboxylates from hydrazones derived from α-diazo esters | |
| Luo et al. | Base-promoted relay reaction of heterocyclic ketene aminals with o-difluorobenzene derivatives for the highly site-selective synthesis of functionalized indoles | |
| Alford et al. | A convenient Fischer indole synthesis of 2, 3′-biindoles | |
| S Ahmed et al. | A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors |